Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Julia Ruff, R.N.

Newlands Health

Disclosure(s): No financial relationships to disclose

Poster(s):

1263 - Dolutegravir/Rilpivirine Switch Study in Persons with HIV and Chronic Kidney Disease: 24-week Assessment of Viral Suppression, Adherence, Treatment Satisfaction and Quality of Life
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET
1268 - Efficacy, safety, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults with HIV-HBV infection - preliminary results
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET